Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression

Clinical Therapeutics

Volumn 33, Issue 9, 2011, Pages 1246-1257

  Jing, Yonghua ^a   Kalsekar, Iftekhar ^a   Curkendall, Suellen M ^b   Carls, Ginger S ^b   Bagalman, Erin ^b   Forbes, Robert A ^c   Hebden, Tony ^a   Thase, Michael E ^d  

^a BRISTOL MYERS SQUIBB   (United States)

^b THOMSON REUTERS   (United Kingdom)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Aripiprazole; Cost; Depression; Health care utilization; Second generation antipsychotic augmentation

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DOPAMINE UPTAKE INHIBITOR; MONAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; OLANZAPINE; QUETIAPINE; SEROTONIN 2 ANTAGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG POTENTIATION; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MENTAL HEALTH CARE; PRESCRIPTION;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DRUG COSTS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION REVIEW; FEMALE; HEALTH EXPENDITURES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; YOUNG ADULT;

EID: 80052981533     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.07.015     Document Type: Article

References (32)

1. Kessler R.C., Berglund P., Demler O., et al. The epidemiology of major depressive disorder. Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
2. Greenberg P.E., Kessler R.C., Birnbaum H.G., et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry 2003, 64:1465-1475.
3. Ivanova J.I., Birnbaum H.G., Kidolezi Y., et al. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin 2010, 26:2475-2484.
4. Trivedi M.H., Rush A.J., Wisniewski S.R., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28-40.
5. Rush A.J., Trivedi M.H., Wisniewski S.R., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
6. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003, 53:649-659.
7. Gibson T.B., Jing Y., Carls G.S., et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care 2010, 16:370-377.
8. Berlim M.T., Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatry 2007, 52:46-54.
9. Corey-Lisle P.K., Birnbaum H.G., Greenberg P.E., et al. Identification of a claims data "signature" and economic consequences for treatment-resistant depression. J Clin Psychiatry 2002, 63:717-726.
10. Greenberg P., Corey-Lisle P.K., Birnbaum H., et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004, 22:363-373.
11. Crown W.H., Finkelstein S., Berndt E.R., et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002, 63:963-971.
12. Russell J.M., Hawkins K., Ozminkowski R.J., et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004, 65:341-347.
13. American Psychiatric Association Practice Guidelines, Treatment of Patients with Major Depressive Disorder 3rd ed. Accessed February 27, 2011. http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx.
14. Abilify (aripiprazole): FDA OKs Abilify for depression Accessed March 1, 2011. http://www.webmd.com/depression/news/20071120/fda-oks-abilify-for-depression.
15. Seroquel XR (quetiapine, extended release tablets): Seroquel XR approved for adjunctive treatment of major depressive disorder (MDD) Accessed March 1, 2011. http://www.empr.com/seroquel-xr-approved-for-adjunctive-treatment-of-major-depressive-disorder-mdd/article/159147/.
16. Symbyax (olanzapine/fluoxetine): Symbyax approved for treatment-resistant depression Accessed March 1, 2011. http://www.emaxhealth.com/1024/25/30037/symbyax-approved-treatment-resistant-depression.html.
17. Symbyax (olanzapine/fluoxetine): Symbyax approved for treatment-resistant depression Accessed March 1, 2011. http://www.ivillage.com/symbyax-approved-treatment-resistant-depression/4-a-113439.
18. Deyo R.A., Cherkin D.C., Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619.
19. Ashcraft M.L., Fries B.E., Nerenz D.R., et al. A psychiatric patient classification system. An alternative to diagnosis-related groups. Med Care 1989, 27:543-557.
20. Petersen T., Papakostas G.I., Posternak M.A., et al. Empirical testing of two models for staging antidepresant treatment resistance. J Clin Psychopharmacol 2005, 25:336-341.
21. Product Information: ABILIFY IM injection, oral solution, oral tablets, orally disintegrating tablets, aripiprazole IM injection, oral solution, oral tablets, orally disintegrating tablets Bristol-Myers Squibb, Editor: Princeton, NJ, Accessed January 20, 2011. http://www.abilify.com/pdf/pi.aspx.
22. Product Information: SEROQUEL XR extended-release oral tablets, quetiapine fumarate extended-release oral tablets Astra Zeneca: Wilmington, DE, Accessed January 20, 2011. http://www1.astrazeneca-us.com/pi/seroquelxr.pdf.
23. ZYPREXA oral tablets, IM injection, ZYPREXA ZYDIS orally disintegrating tablets, olanzapine oral tablets, IM injection, orally disintegrating tablets [prescribing information] Indianapolis, Ind: Eli Lilly and Company, Accessed January 20, 2011. http://pi.lilly.com/us/zyprexa-pi.pdf.
24. SYMBYAX oral capsule, olanzapine and fluoxetine hydrochloride oral capsule [prescribing information] Indianapolis, Ind: Eli Lilly and Company, Accessed January 20, 2011. http://pi.lilly.com/us/symbyax-pi.pdf.
25. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004, 59:702-706.
26. Connolly K.R., Thase M.E. If at first you don't succeed. A review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011, 71:43-64.
27. Taneja C, Oster G, Jing Y, et al. Cost-effectiveness of atypical antipsychotics as adjunctive therapy in adult patients with major depressive disorder (MDD). Poster presented at International Society for Pharmacoeconomics and Outcomes Research, 15th Annual International Meeting, Atlanta, Ga, May 15-19, 2010.
28. Kim E., Maclean R., Ammerman D., et al. Time to psychiatric hospitalization in patients with bipolar disorder treated with mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis. Clin Ther 2009, 31:836-848.
29. Jing Y., Kim E., You M., et al. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. J Med Econ 2009, 12:104-113.
30. Leslie D.L., Mohamed S., Rosenheck R.A. Off-label use of antipsychotic medications in the Department of Veterans Affairs health care system. Psychiatr Serv 2009, 60:1175-1181.
31. Kogut S.J., Yam F., Dufresne R. Prescribing of antipsychotic medication in a Medicaid population: use of polytherapy and off-label dosages. J Manag Care Pharm 2005, 11:17-24.
32. Thase ME, Jing Y, Guo Z, et al. Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder in an outpatient setting from 2003 to 2008. Poster presented at: US Psychiatric and Mental Health Congress, Orlando, Fla, November 18-21, 2010.